A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2017
At a glance
- Drugs TAS 119 (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 12 Jun 2017 Planned End Date changed from 1 May 2017 to 1 Nov 2018.
- 12 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Nov 2018.
- 24 Sep 2015 Status changed from active, no longer recruiting to recruiting, as reported by ClinicalTrials.gov.